Navigation Links
OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
Date:10/29/2008

Q3 2008 Contracts Total $3,970,647, up 137% Over Q3 2007

FT. LAUDERDALE, Fla., Oct. 29 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture solutions for clinical trials, today announced another momentous quarter for new business. Signed contracts through the first 3 quarters of 2008, totaling $15.8M, are exceeding projected expectations for the year.

"It is not an accident that OmniComm continues to grow and prosper in these challenging economic times," said Stephen Johnson, COO of OmniComm. "We work hard to be in tune with our customers' needs and we are steadfast in our commitment to delivering an excellent product backed by even better customer service. We are flattered by the commitment that our customers have shown to us but we must not become complacent if we are going to live up to their expectations."

Thomas Wells, Vice President of Technology for OmniComm added, "Our customers are becoming EDC experts and expect much more than just the typical data collection and cleaning. Business intelligence and integration with external applications for better data handling have become necessities for our customers to meet the challenges of their expedited clinical timelines. OmniComm's vision for early 2009 includes the creation of a Centralized Data Hub where eClinical services can be seamlessly integrated with our clients' systems and repositories. This solution will empower our clients to take control of their data and better leverage core industry standards like CDISC and CDASH."

OmniComm continues to increase its customer base with a strong mix of new customer business coupled with steady, recurring business from its existing loyal customers. The following is a breakdown of new business for Q3, 2008.

Q3 New Contracts 2008:

Industry leading academic research center and best-in-class contract research organization choose OmniComm for Technol
'/>"/>

SOURCE OmniComm Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference
2. Avantis Medical Systems, Inc. Announces Key Leadership Appointments
3. CEOs Letter to Shareholders of Imaging Diagnostic Systems, Inc.
4. Concuity Announces Partnership with Financial Healthcare Systems, LLC
5. StemCor Systems, Inc. Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform
6. Solei Systems, Inc., Announces That the Company Is Now Publicly Traded
7. Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
8. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
9. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
10. Cephalon Reports Another Strong Quarter
11. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, Inc. ... positive interim results from a poster presented today ... label randomised phase III trial of the efficacy ... patients receiving cisplatin (Cis) monotherapy for standard risk ... American Society of Clinical Oncology (ASCO) 2015 Annual ...
(Date:6/1/2015)... Minn. and SOUTH SAN FRANCISCO, ... Ventures, the venture arm of Baxter International Inc. (NYSE: ... Development, LLC ("VPD") today announced the formation of Vitesse ... initiated by Baxter Ventures to focus on the development ... immunology, hematology, and oncology. Following the spin-off of Baxter ...
(Date:6/1/2015)... June 1, 2015 Esperance Pharmaceuticals Inc. today ... lead candidate EP-100 in ovarian cancer patients resistant to ... seek and destroy cancer cells that overexpress luteinizing hormone-releasing ... over-expressed in a wide range of cancers. ... trial of EP-100 were presented at the 2015 ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... ... camera during an operation he performed for his Discovery Channel television special: Silent Stalker: ... ... Show used VizVOCUS,s popular "plug and play" medical camera during an ...
... England , May 25, 2010 Executives from Heptares,Therapeutics (Welwyn ... of the agreement under which O2h provides multi-FTE -synthetic,chemistry services to support ... , ... said, "We are happy to have signed,this new contract with O2h; they ...
... China , May 25 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: ... leading over-the-counter Hepatitis B medicine,Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), ... it has,commenced assembly of its production line for its proprietary Zushima ... ...
Cached Biology Technology:VizVOCUS's Digital Camera Used by Dr. Mehmet Oz on Discovery Channel Special 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 2Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 4
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Mayo Clinic-led researchers is first to devise a system ... killer that hunts down and destroys cancer cells -- ... an advanced electronic article of Nature Biotechnology. , The ... cells, and then redirected the virus to attack diseased, ...
... prenatal care, new research suggests that early infection may ... on the immune system. Researchers at the University of ... a one-time infection as newborns didn't learn as well ... after their immunity was challenged. The research is in ...
... that the antibiotic minocycline might help alleviate HIV's negative ... that can develop even though antiretroviral therapy controls the ... with simian immunodeficiency virus (SIV), a very close relative ... to brain cells, less brain inflammation, and less virus ...
Cached Biology News:Mayo Clinic Researchers Create 'Obedient Virus'; First Step To Use Measles Virus Against Cancer 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 3Antibiotic might fight HIV-induced neurological problems 2Antibiotic might fight HIV-induced neurological problems 3
Request Info...
Bovine Serum Albumin Peroxidase Stabilizer Solution, 1 L...
SAIVI Alexa Fluor 680 injectable contrast agent *bovine serum albumin*...
... Lysate contains the cellular components necessary for ... elongation and termination factors) but has not ... is used primarily for the isolation of ... of endogenous globin mRNA. Untreated Lysate is ...
Biology Products: